Monikongkona Boruah, Riyaz Ahmad Mir, Sameer Rastogi, Kapil Sikka, Shipra Agarwal. TIM-3 as a therapeutic target in anaplastic thyroid carcinoma: Preclinical and transcriptomic evidence supporting a new immunotherapy avenue. // Clinical Immunology. – DOI: 10.1016/j.clim.2026.110761. – URL: https://www.sciencedirect.com/science/article/pii/S1521661626000999?dgcid=rss_sd_all
Monikongkona Boruah, Riyaz Ahmad Mir, Sameer Rastogi, Kapil Sikka, & Shipra Agarwal TIM-3 as a therapeutic target in anaplastic thyroid carcinoma: Preclinical and transcriptomic evidence supporting a new immunotherapy avenue. Clinical Immunology. https://doi.org/10.1016/j.clim.2026.110761
Monikongkona Boruah, et al. “TIM-3 as a therapeutic target in anaplastic thyroid carcinoma: Preclinical and transcriptomic evidence supporting a new immunotherapy avenue.” Clinical Immunology. doi:10.1016/j.clim.2026.110761.
@article{Boruah,
title = {TIM-3 as a therapeutic target in anaplastic thyroid carcinoma: Preclinical and transcriptomic evidence supporting a new immunotherapy avenue},
author = {Boruah, Monikongkona and Mir, Riyaz Ahmad and Rastogi, Sameer and Sikka, Kapil and Agarwal, Shipra},
journal = {Clinical Immunology},
doi = {10.1016/j.clim.2026.110761},
url = {https://www.sciencedirect.com/science/article/pii/S1521661626000999?dgcid=rss_sd_all}
}